Medical Clinic 1, Department of Medicine, University Hospital Erlangen, Friedrich-Alexander-University, Erlangen, Germany.
Medical Clinic 1, Department of Medicine, University Hospital Erlangen, Friedrich-Alexander-University, Erlangen, Germany.
Gastroenterology. 2019 Nov;157(5):1310-1322.e13. doi: 10.1053/j.gastro.2019.07.031. Epub 2019 Jul 25.
BACKGROUND & AIMS: Interferon lambda (IFNL) is expressed at high levels by intestinal epithelial cells (IECs) and mucosal immune cells in response to infection and inflammation. We investigated whether IFNL might contribute to pathogenesis of Crohn's disease (CD).
We obtained serum samples and terminal ileum biopsies from 47 patients with CD and 16 healthy individuals (controls). We measured levels of IFNL by enzyme-linked immunosorbent assay and immunohistochemistry and location of expression by confocal microscopy. Activation of IFNL signaling via STAT1 was measured in areas of no, mild, moderate, and severe inflammation and correlated with Paneth cell homeostasis and inflammation. IFNL expression and function were studied in wild-type mice and mice with intestinal epithelial cell-specific (ΔIEC) disruption or full-body disruption of specific genes (Mlkl, Stat1, Casp8, Casp8Ripk3, Casp8Tnfr, Casp8Mlkl, and Nod2 mice). Some mice were given tail vein injections of a vector encoding a secreted form of IFNL. Intestinal tissues were collected from mice and analyzed by immunohistochemistry and immunoblots. We generated 3-dimensional small intestinal organoids from mice and studied the effects of IFNL and inhibitors of STAT-signaling pathway.
Patients with CD had significant increases in serum and ileal levels of IFNL compared with controls. Levels of IFNL were highest in ileum tissues with severe inflammation. High levels of IFNL associated with a reduced number of Paneth cells and increased cell death at the crypt bottom in inflamed ileum samples. Intestinal tissues from the ileum of wild-type mice injected with a vector expressing IFNL had reduced numbers of Paneth cells. IFNL-induced death of Paneth cells in mice did not occur via apoptosis, but required Mixed Lineage Kinase Domain Like (MLKL) and activation of Signal transducer and activator of transcription 1 (STAT1). In organoids, inhibitors of Janus kinase (JAK) signaling via STAT1 (glucocorticoids, tofacitinib, or filgotinib) reduced expression of proteins that mediate cell death and prevented Paneth cell death.
Levels of IFNL are increased in serum and inflamed ileal tissues from patients with CD and associated with a loss of Paneth cells. Expression of a secreted form of IFNL in mice results in loss of Paneth cells from intestinal tissues, via STAT1 and MLKL, controlled by caspase 8. Strategies to reduce IFNL or block its effects might be developed for treatment of patients with CD affecting the terminal ileum.
干扰素 lambda (IFNL) 在受到感染和炎症的刺激时,由肠道上皮细胞 (IECs) 和黏膜免疫细胞高水平表达。我们研究了 IFNL 是否可能有助于克罗恩病 (CD) 的发病机制。
我们从 47 名 CD 患者和 16 名健康个体(对照组)中获得了血清样本和末端回肠活检。我们通过酶联免疫吸附测定法和免疫组化法测量 IFNL 的水平,并通过共聚焦显微镜测量其表达位置。通过测量无、轻度、中度和重度炎症区域中 IFNL 信号通过 STAT1 的激活情况,并将其与潘氏细胞的稳态和炎症相关联。我们在野生型小鼠和肠道上皮细胞特异性 (ΔIEC) 破坏或全身特定基因 (Mlkl、Stat1、Casp8、Casp8Ripk3、Casp8Tnfr、Casp8Mlkl 和 Nod2 小鼠) 破坏的小鼠中研究了 IFNL 的表达和功能。一些小鼠接受了尾静脉注射编码分泌型 IFNL 的载体。从小鼠中收集肠道组织,并通过免疫组化和免疫印迹进行分析。我们从小鼠中生成了 3 维小肠类器官,并研究了 IFNL 和 STAT 信号通路抑制剂的作用。
与对照组相比,CD 患者的血清和回肠组织中 IFNL 水平显著升高。IFNL 水平在严重炎症的回肠组织中最高。在炎症回肠样本中,高 IFNL 水平与潘氏细胞数量减少和隐窝底部细胞死亡增加有关。接受表达 IFNL 的载体注射的野生型小鼠的肠道组织中潘氏细胞数量减少。IFNL 诱导的小鼠潘氏细胞死亡不是通过细胞凋亡发生的,而是需要混合谱系激酶结构域样 (MLKL) 和信号转导和转录激活因子 1 (STAT1) 的激活。在类器官中,通过 STAT1 抑制 Janus 激酶 (JAK) 信号通路 (糖皮质激素、托法替尼或 filgotinib) 可降低介导细胞死亡的蛋白质的表达,并防止潘氏细胞死亡。
CD 患者的血清和炎症性回肠组织中 IFNL 水平升高,并与潘氏细胞缺失有关。在小鼠中表达分泌型 IFNL 会导致肠组织中的潘氏细胞通过 STAT1 和 MLKL 丢失,由半胱天冬酶 8 控制。为了治疗影响末端回肠的 CD 患者,可能会开发出减少 IFNL 或阻断其作用的策略。